Ro's Integrated Care Model: Beyond Medication Access According to information on ro.co , the Ro Body Program integrates multiple components designed to support sustainable weight management: Medical Oversight Component : Licensed healthcare provider evaluation and approval Ongoing medication management and dose optimization Side effect monitoring and management strategies Lab testing when clinically indicated Regular progress monitoring and treatment adjustments Insurance Navigation Component : Dedicated concierge team for coverage verification Prior authorization preparation and submission Appeals assistance if coverage denied Alternative coverage exploration Coordination with insurance providers Behavioral Support Component : Health coaching from licensed providers Evidence-based nutrition guidance Physical activity recommendations Sleep and stress management strategies Habit formation support Technology Platform Component : HIPAA-compliant secure messaging Digital weight and dose tracking Progress visualization tools Educational content library Video consultation capability Pharmaceutical Component : Access to FDA-approved brand-name medications Multiple medication options (semaglutide and tirzepatide) Flexible fulfillment pathways (insurance or cash-pay) Direct-to-home delivery or pharmacy pickup GLP-1 Medications Available Through Ro: Comprehensive Analysis of Options Semaglutide-Based Options: Wegovy and Ozempic Wegovy (Semaglutide 2.4 mg): FDA-Approved for Chronic Weight Management FDA Approval Status : According to FDA documentation, Wegovy received approval on June 4, 2021, for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, to be used as an adjunct to reduced-calorie diet and increased physical activity

You'll receive an easy-to-use at-home test kit that's nearly painless to collect a small sample from your arm
Frequently asked questions Start by increasing your water intake and adding electrolytes, since dehydration is one of the most common triggers
The primary endpoint was to prove non-inferiority of the combination compared to degludec and superiority compared to liraglutide
Initially intended for those with Type 2 diabetes because of their effectiveness in balancing blood sugar levels and their impact on insulin sensitivity, doctors quickly realized their off-label potential for weight loss, leading to their widespread popularity today
While such effects can lead to noticeable weight loss, they are only prescribed for individuals who meet specific medical requirements